NEW STUDY PUBLISHED BY IBG RESEARCHERS ON MANTLE CELL LYMPHOMA
Lymphoid Cancer Genomics research group and project partners published their findings in the Cells journal (IF: 7.7) on the identification of prognostically-significant genes and tumor-infiltrating immunocytes in mantle cell lymphoma.
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) subtype characterized by high expression of the CCND1 and SOX11 genes. It is generally associated with clinically poor outcomes despite recent improvements in therapeutic approaches; and the genes associated with the development and prognosis of MCL are still largely unknown.
This collaborative research project included IBG’s Lymphoid Cancer Genomics research group leader and group members Assoc. Prof. Can KÜÇÜK, Esra Esmeray SÖNMEZ, Tevfik HATİPOĞLU, Deniz KURŞUN, Dr. Xiaozhou HU, Dr. Burcu AKMAN. They collaborated with Dr. Hongling YUAN (Department of Basic Oncology), Assoc. Prof. Ayça ERŞEN DANYELİ and Prof. Dr. Sermin ÖZKAL (Department of Medical Pathology), Dr. Aybüke OLGUN and Prof. Dr. İnci ALACACIOĞLU (Department of Hematology), Prof. Dr. Taner Kemal ERDAĞ (Department of Otorhinolaryngology) from Dokuz Eylül University.Also, Prof. Dr. Hua YOU from Chongqing Medical University in China provided invaluable contributions to this interdisciplinary project as research partner. In this project supported by the TÜBİTAK 3501 program, differentially expressed mRNAs, lncRNAs, and alternative transcripts have been identified that led to the discovery of novel candidate oncogenes and tumor suppressor genes potentially associated with development of MCL. Furthermore, prognostically significant transcripts as well as tumor-infiltrating immunocytes have been determined. Importantly, high-risk MCL patient subgroups were identified through integrative analysis of tumor-infiltrating immunocytes and oncogenesis-associated transcripts.
Based on the results of this study, the expression levels of oncogenesis-related transcripts and/or the ratios of tumor-infiltrating immunocytes can be used for improved prognostication, thereby contributing to better disease management.